SIETES :: 92794 citas

Resultados de la búsqueda por NEUROLOGÍA REFINAR BÚSQUEDA

1.

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019:24 de junio. [Ref.ID 103160]

2.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie MA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019;92:5 de marzo. [Ref.ID 103132]

3.

Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]

4.

Liu B, Luo Z, Pinto JM, Shiroma EJ, Tranah GJ, Wirdefeldt K, Fang F, Harris TB, Chen H. Relationship between poor olfaction and mortality among community-dwelling older adults: a cohort study. Ann Intern Med 2019:30 de abril. [Ref.ID 103093]

5.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]

6.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

7.

Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]

8.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

9.

Hurley R. Medical cannabis: no NHS patients have benefited from law change, say campaigners. BMJ 2019;364:15 de febrero. [Ref.ID 103033]

10.

Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]

11.

Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]

12.

Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]

13.

Sánchez Caballero D. El Gobierno da largas sobre la regulación del cannabis medicinal hasta que se pronuncie la OMS . eldiario.es 2019:28 de enero. [Ref.ID 103012]

14.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

15.

Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, for the VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:3 de enero. [Ref.ID 102995]

16.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]

17.

Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2018;18:febrero. [Ref.ID 102909]

18.

Anónimo. Ocrélizumab et sclérose en plaques. Prescrire 2018;38:890-2. [Ref.ID 102904]

19.

Cooney E. Novartis unit teams up with medical marijuana producer, marking milestone for pharma. STAT Daily Recap 2018:18 de diciembre. [Ref.ID 102888]

20.

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]